GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Jan 2024 07:00 AM
RNS
European Commission authorises Omjjara in the EU
19 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
18 Jan 2024 05:00 PM
RNS
Holding(s) in Company
17 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
17 Jan 2024 07:00 AM
RNS
GSK completes sale of shares in Haleon plc
16 Jan 2024 04:40 PM
RNS
GSK announces intention to sell shares in Haleon
16 Jan 2024 03:30 PM
RNS
Director/PDMR Shareholding
10 Jan 2024 07:00 AM
RNS
Nucala approved in China for use in severe asthma
09 Jan 2024 07:00 AM
RNS
GSK enters agreement to acquire Aiolos Bio
02 Jan 2024 03:00 PM
RNS
Total Voting Rights
21 Dec 2023 03:30 PM
RNS
Director/PDMR Shareholding
20 Dec 2023 04:44 PM
RNS
Publication of EMTN Suppl.Prospcts
18 Dec 2023 07:00 AM
RNS
Jemperli plus Zejula Trial Meets Endpoint
13 Dec 2023 03:30 PM
RNS
Director/PDMR Shareholding
12 Dec 2023 07:00 AM
RNS
Japan accepts Arexvy filing for at risk adults
11 Dec 2023 07:00 AM
RNS
Jemperli plus chemotherapy EU authorisation
04 Dec 2023 03:02 PM
RNS
GSK publishes provisional 2024 dividend dates
01 Dec 2023 03:00 PM
RNS
Total Voting Rights
30 Nov 2023 09:00 AM
RNS
Block Listing Application
29 Nov 2023 03:23 PM
RNS
Holding(s) in Company
27 Nov 2023 07:00 AM
RNS
GSK announces positive DREAMM-7 headline results
21 Nov 2023 03:30 PM
RNS
Director/PDMR Shareholding
15 Nov 2023 03:00 PM
RNS
Block listing Interim Review
13 Nov 2023 03:30 PM
RNS
Director/PDMR Shareholding
13 Nov 2023 07:00 AM
RNS
GSK receives positive CHMP opinion for momelotinib
01 Nov 2023 03:00 PM
RNS
Total Voting Rights
01 Nov 2023 07:00 AM
RNS
3rd Quarter Results
30 Oct 2023 07:00 AM
RNS
Jemperli trial meets overall survival endpoint
26 Oct 2023 07:00 AM
RNS
NMPA approves Vocabria+Rekambys in China
25 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
25 Oct 2023 07:00 AM
RNS
New data for Arexvy, GSK’s RSV vaccine
20 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
18 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
17 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
16 Oct 2023 07:00 AM
RNS
Jemperli plus chemotherapy positive CHMP opinion
13 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
12 Oct 2023 03:30 PM
RNS
Director/PDMR Shareholding
11 Oct 2023 07:00 AM
RNS
Zantac (ranitidine) litigation
10 Oct 2023 11:00 AM
RNS
Holding(s) in Company
09 Oct 2023 07:00 AM
RNS
GSK and Zhifei announce vaccine partnership
06 Oct 2023 07:00 AM
RNS
GSK completes sale of shares in Haleon plc
05 Oct 2023 04:46 PM
RNS
GSK announces intention to sell shares in Haleon
02 Oct 2023 03:00 PM
RNS
Total Voting Rights
27 Sep 2023 03:00 PM
RNS
Directorate Change
25 Sep 2023 07:00 AM
RNS
GSK RSV vaccine for older adults approved in Japan
21 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
19 Sep 2023 07:00 AM
RNS
Apretude for PrEP receives EMA approval
18 Sep 2023 07:00 AM
RNS
FDA approves Ojjaara (momelotinib)
13 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding
11 Sep 2023 03:30 PM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

UK 100

Latest directors dealings